...Nilton Custodio; Marco Malaga; Rosa Montesinos; Diego Chambergo-Michilot; Fiorella Baca; Juan Carlos Carbajal; Jose Carlos Huilca; Eder Herrera-Perez; David Lira; Monica M. Diaz; Serggio Lanata Introduction: As disease-modifying therapies become available for Alzheimer’s disease (AD), detection...

...Anna-Lena Richter; Marlies Diepeveen-de Bruin; Michiel G.J. Balvers; Lisette C.P.G.M. De Groot; Peter Paul De Deyn; Sebastiaan Engelborghs; Renger F. Witkamp; Yannick Vermeiren Introduction: Studies suggest a role of vitamin D in the progression and symptomatology of Alzheimer’s disease (AD...

... of 8,330.6 person-years of follow-up, 101 persons were diagnosed with dementia, including 74 with Alzheimer's disease (AD) and 26 with vascular dementia (VaD). The high (vs. low) tertile of lifelong CR score was associated with multivariable-adjusted hazards ratios (95% confidence interval) of 0.28 (0.14...

...Maoni Jia; Yafei Wu; Chaoyi Xiang; Ya Fang Introduction: This study aimed to develop novel machine learning models for predicting Alzheimer’s disease (AD) and identify key factors for targeted prevention. Methods: We included 1,219, 863, and 482 participants aged 60+ years with only...

...Lijuan Tang; Zhenglin Zhang; Feifan Feng; Li-Zhuang Yang; Hai Li Introduction: Alzheimer’s disease (AD) is the most prevalent type of dementia and can cause abnormal cognitive function and progressive loss of essential life skills. Early screening is thus necessary for the prevention...

..., the incidence of epilepsy in patients with Alzheimer’s disease (AD) is increasing, drawing attention to the pathological relationship between the two conditions. Clinical studies have suggested the protective action of antiepileptic agents on dementia; however, the underlying mechanism remains unknown. We...

...Rui Wang; Yi Zhu; Lan-Fang Qin; Zhi-Guo Xu; Xi-Ren Gao; Chong-Bin Liu; Guo-Tong Xu; Yi-Zhu Chen Introduction: Stem cell-based regenerative medicine has provided an excellent opportunity to investigate therapeutic strategies and innovative treatments for Alzheimer’s disease (AD). However...

...Jonathan P Scott; Donnchadh F Murphy; Rupert F Noad Introduction: Visual and spatial perception (VSP) are cognitive domains frequently assessed in the screening and neuropsychological assessment of dementia. Evidence suggests that VSP impairment is common in the early stages of Alzheimer’s disease...

... Alzheimer’s disease (AD) risk. Although brain amyloid load is a recognized hallmark of pre-symptomatic AD, its relationship to increased BP is less known. The objective of this study was to examine the relationship of BP to brain estimates of amyloid-β (Aβ) and standard uptake ratio (SUVr). We hypothesized...

.... Social connectedness Nursing homes Facility factors Alzheimer’s disease Dementia National Institutes of Health (NIH) 10.13039/100000002 Of people with Alzheimer’s disease and other related dementias (ADRD), three quarters will spend time in nursing homes before 80 years of age...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Activities of daily living Alzheimer’s disease Discrepancy scores Insight Anosognosia Wellcome Trust 10.13039...

... Introduction: Several recent research studies show high performance of blood biomarkers to identify Alzheimer’s disease also in the pre-dementia mild cognitive impairment (MCI) stage, but data from the routine clinical care memory clinic setting are needed. Methods: We examined plasma samples of 144 memory...

... in patients with Alzheimer’s disease (AD). However, no studies have examined its relationship with AD-related biomarkers. Methods: One-hundred twenty-one older adults (intact, amnestic mild cognitive impairment, mild AD) completed the QDRS, and three biomarkers (amyloid deposition via positron emission...

...Seon Young Ryu; Yun Jeong Hong; SeongHee Ho; Jee Hyang Jeong; Kee Hyung Park; SangYun Kim; Min Jeong Wang; Seong Hye Choi; Dong Won Yang Introduction: Subjective cognitive decline (SCD) can be considered as the preclinical manifestation of Alzheimer’s disease (AD). The National Institute on Aging...

...Karin Persson; Trine H. Edwin; Anne-Brita Knapskog; Gro G. Tangen; Geir Selbæk; Knut Engedal Introduction: One pathological hallmark of Alzheimer’s disease (AD) is atrophy of medial temporal brain regions that can be visualized on magnetic resonance imaging (MRI), but not all patients will have...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Alzheimer’s disease Mexican American APOE4 Cognition Health disparities National Institutes of Health (NIH...

... significant changes in Finland during the 2020s. A similar process is likely to occur also in several European countries. For cognitive screening of early Alzheimer’s disease (AD), using outdated norms and cutoff scores may negatively affect clinical accuracy. The aim of the present study was to examine...

... of Alzheimer’s disease (AD), baseline biomarkers to predict progression are clinically important. In the present study, cognitive trajectories during a 24-month period were compared between amyloid-positive SCD (A+SCD) and amyloid-negative SCD (A−SCD) subjects, and biomarkers associated with memory decline were...

...James R. Hall; Leigh A. Johnson; Fan Zhang; Melissa Petersen; Arthur W. Toga; Yonggang Shi; David Mason; Robert A. Rissman; Kristine Yaffe; Sid E. O’Bryant; for the HABLE Study Introduction: Alzheimer’s disease (AD) is the most frequently occurring neurodegenerative disease; however, little work...

...: Donepezil 23 mg is considered for Alzheimer’s disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence. We investigated whether body weight (BW) differs based on the presence of AEs, and which baseline factors were relevant to the safety...